Indomethacin
- Generic Name
- Indomethacin
- Brand Names
- Indocin, Tivorbex
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16ClNO4
- CAS Number
- 53-86-1
- Unique Ingredient Identifier
- XXE1CET956
- Background
Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlorobenzoyl)25-methoxy-2-methylindole-3-ace...
- Indication
Oral indometacin is indicated for symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.
...
- Associated Conditions
- Acute Gouty Arthritis, Joint Pain, Moderate to Severe Osteoarthritis, Moderate to Severe Rheumatoid Arthritis, Moderate to severe ankylosing spondylitis, Myalgia, Patent Ductus Arteriosus (PDA), Acute Shoulder Pain
- Associated Therapies
- -
Blood Brain Flow and Exercise
- Conditions
- Interventions
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 80
- Registration Number
- NCT02653638
- Locations
- 🇺🇸
Gymnasium-Natatorium, Madison, Wisconsin, United States
Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
- Conditions
- Interventions
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- The Cooper Health System
- Target Recruit Count
- 192
- Registration Number
- NCT02641561
- Locations
- 🇺🇸
Cooper Hospital, Camden, New Jersey, United States
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Brooklyn ImmunoTherapeutics, LLC
- Target Recruit Count
- 105
- Registration Number
- NCT02609386
- Locations
- 🇬🇧
Queen Elizabeth University Hospital Glasgow, Glasgow, United Kingdom
🇺🇸Monter Cancer Center - North Shore LIJ, New Hyde Park, New York, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
Performance of 13C Mannitol for in Vivo Measurement of Small Intestinal Permeability
- Conditions
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT02603822
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Intrathecal Opioid Study
- Conditions
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- University of Witwatersrand, South Africa
- Target Recruit Count
- 100
- Registration Number
- NCT02577809
- Locations
- 🇿🇦
Rahima Moosa Mother and Child Hospital, Johannesburg, Gauteng, South Africa
Nifedipine or Nifedipine Plus Indomethacin for Treatment of Acute Preterm Labor
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2021-11-24
- Target Recruit Count
- 49
- Registration Number
- NCT02438371
- Locations
- 🇺🇸
Memorial Hermann Hospital Texas Medical Center, Houston, Texas, United States
Non-inferiority of Pharmacological Prevention Alone Versus Pancreatic Stents to Prevent Post-ERCP Pancreatitis
- Conditions
- Interventions
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2015-11-06
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT02368795
- Locations
- 🇮🇷
Shariati hospital, Tehran, Iran, Islamic Republic of
Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Hong Huang
- Target Recruit Count
- 256
- Registration Number
- NCT02221219
- Locations
- 🇺🇸
Kentucky Childrens Hospital Neonatal Intensive Care Unit, Lexington, Kentucky, United States
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- Conditions
- Interventions
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- North American Consortium for Histiocytosis
- Target Recruit Count
- 1400
- Registration Number
- NCT02205762
- Locations
- 🇺🇸
Children's Medical Center Dallas, UT Southwestern, Dallas, Texas, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis
- Conditions
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 192
- Registration Number
- NCT02183168
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.